SEC Filing Summary: PerkinElmer, Inc. (Form 10-Q)
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for PerkinElmer, Inc. (Note: The metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly period ended June 29, 2003, and the six-month period ended on the same date. The company operates in three primary segments: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. During this period, the company continued integrating its Life Sciences and Analytical Instruments businesses into a single reporting segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 29, 2003 |
3 Months Ended June 30, 2002 |
6 Months Ended June 29, 2003 |
6 Months Ended June 30, 2002 |
|---|---|---|---|---|
| Sales | $377,124 | $383,096 | $735,573 | $729,389 |
| Operating Income | $30,023 | $17,409 | $49,291 | $2,512 |
| Net Income (Loss) | $8,398 | $(9,096) | $10,760 | $(156,456) |
| Diluted EPS | $0.07 | $(0.07) | $0.08 | $(1.25) |
| Cash & Equivalents | $144,623 | — | — | — |
| Operating Cash Flow (6mo) | — | — | $60,911 | $(19,483) |
| Total Debt (Approx.) | — | — | ~$746M | — |
Note: The 2002 six-month net loss includes a $117.8 million after-tax charge for goodwill impairment due to the adoption of SFAS No. 142.
Material Changes vs. Prior Period
- Profitability Improvement: Operating income for the six months ended June 29, 2003, surged to $49.3 million compared to $2.5 million in the prior year. This was driven by cost savings from business integration, restructuring reversals, and improved segment performance.
- Restructuring Activity: The company recorded a net reversal of $2.7 million in restructuring charges for the quarter, primarily due to lower-than-expected severance costs in 2002 plans, partially offset by new charges for 2001 and 2003 plans.
- Segment Performance:
- Life and Analytical Sciences: Sales declined slightly (3% QoQ), but operating profit increased 60% due to integration savings.
- Optoelectronics: Sales increased 8% QoQ, with operating profit rising 131% due to higher capacity utilization and cost controls.
- Fluid Sciences: Sales and operating profit declined (12% and 19% respectively) due to weakness in aerospace and semiconductor markets.
- Debt Reduction: The company prepaid $30 million of its term loan and $32.5 million of zero-coupon convertible debentures during the six-month period. An additional $157 million of debentures were scheduled for redemption in August 2003 using escrowed funds.
Guidance, Outlook, and Risks
- Outlook: Management expects operations to generate sufficient cash to fund expenses and interest payments in the near term. Capital expenditures are expected to be at least equal to the current six-month level, dependent on economic conditions.
- Dividends: The Board declared a quarterly cash dividend of $0.07 per share.
- Key Risks:
- Cyclical Markets: Results are sensitive to downturns in pharmaceutical, biomedical, semiconductor, and aerospace industries.
- Debt Obligations: Substantial indebtedness (~$746 million) limits flexibility and increases vulnerability to economic conditions. Covenants require maintaining specific financial ratios.
- Legal Proceedings: The company is defending a class action lawsuit regarding alleged misleading statements and a patent infringement suit filed by Enzo Biochem, Inc.
- Foreign Exchange: Approximately 51% of sales are international, exposing the company to currency fluctuation risks.
Investor Verification Checklist
- Debt Redemption: Verify the successful redemption of the remaining $157 million zero-coupon convertible debentures scheduled for August 7, 2003.
- Covenant Compliance: Confirm continued compliance with financial covenants in the senior credit facility and 8 7/8% notes, particularly regarding leverage and interest coverage ratios.
- Legal Exposure: Monitor the status of the class action lawsuit and the Enzo Biochem patent dispute for potential material liabilities.
- Segment Mix: Assess the sustainability of margin improvements in the Life and Analytical Sciences segment given the shift to lower-margin products mentioned in the filing.
- Working Capital: Review the trend in accounts receivable and inventory management, which contributed significantly to the improvement in operating cash flow.